StockData

Elanco Animal Health vs Zoetis

ELAN and ZTS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ELAN and ZTS compare

Zoetis is the larger company, worth 2.7 times as much as Elanco Animal Health ($34.5B against $12.9B).

Elanco Animal Health grew revenue faster over the last twelve months (12.0% versus 1.5% for Zoetis).

Zoetis keeps more of each dollar of sales as profit, with a net margin of 27.5% compared with −4.0% at Elanco Animal Health.

Zoetis pays a dividend yielding 1.9%; Elanco Animal Health does not pay one.

Zoetis scores higher on the StockData Score (17 against 9 for Elanco Animal Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricELANZTS
Size and price
Market cap$12.9B$34.5B
Share price$25.85$83.48
Change, 1 year22.6%−30.9%
Change, 5 years−14.5%−61.9%
Beta (5Y)0.120.06
Employees9,40015K
StockData Score
Total score917 (better)
Valuation score15 (better)
Growth score3 (better)2
Performance score35 (better)
Health score23 (better)
Dividend score02 (better)
Valuation
P/E–13.7×
P/S2.6× (better)3.6×
P/B2.0× (better)11.0×
EV/EBITDA30.9×10.5× (better)
P/FCF34.1×14.9× (better)
PEG–1.34
FCF yield2.9%6.7% (better)
Fair value$11.31$154.11
Margin of safety−129%45.8% (better)
Growth
Revenue growth (TTM)12.0% (better)1.5%
Revenue growth, 5Y average7.6% (better)7.2%
Net income growth (TTM)−146%0.96% (better)
EPS growth (TTM)−149%5.6% (better)
EPS growth, 5Y average–12.0%
Profitability
Gross margin55.4%71.5% (better)
Net margin−4.0%27.5% (better)
FCF margin7.5%24.3% (better)
Return on equity−3.0%64.4% (better)
Financial health
Debt / equity0.59 (better)2.87
Net debt / EBITDA6.431.85 (better)
Current ratio2.053.08 (better)
Altman Z-score1.444.07 (better)
Piotroski F-score68 (better)
Dividends and buybacks
Dividend yield–1.9%
Years of dividend growth–13
Dividend growth, 5Y average–19.0%
Buyback yield–10.6%
Shareholder yield0.00%12.5% (better)
Ownership
Held by institutions113%96.1%
Held by insiders1.1%0.08%
Insider net buying, 12 months$2.5M (better)−$1.7M
Superinvestors holding–3
Short interest, % of float6.7%4.1%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.